 |
 |
|
|
|
|
(Clinical Indication:Arteriosclerosis obliterans )
A discovery program for new anti-platelet drug had started from 1993 as collaboration between Dr. H. Hidaka and Otsuka Pharmaceutical Co. Ltd. K-134 was selected as a clinical candidate for anti-platelet drug with potent anti-intimal hyperplasic activity.
Phase I data demonstrate that K-134 exhibits good efficacy on platelet aggregation inhibition. In addition, K-134 also exhibits potent anti-intimal hyperplasic activity in animal models.
All patent rights for world-wide marketing were devolved from Otsuka Pharmaceutical Co., Ltd. by August 2002, and then out-licensed to Kowa Co., Ltd. in September 2002. Phase IIa trials were successfully completed in the U.S. and Japan.
In 2012, Phase IIb trial is initiated in Japan.
(Clinical Indication:Glaucoma)
K-115, isoquinolinesulfonamide compound, is a selective Rho-kinase inhibitor; being developed as an anti-glaucoma drug with intraocular pressure (IOP)-lowering activities. Preclinical studies and Phase I trials of K-115 demonstrate that instillations of K-115 reduced IOP. In addition, K-115 demonstrated neuroprotection of retinal ganglion cells which are known to be injured in glaucoma. DWTI licensed out the world-wide rights of K-115 to Kowa Co., Ltd. in September 2002.
Phase II trial was successfully completed in Japan.
In 2011, Phase III trial is initiated in Japan.
(Clinical Indication:Cancer)
HMN-214 was invented as an anti-cancer drug under collaboration between Dr. Hidaka and Nippon Shinyaku Co. Ltd. A study by using Drug Western method indicates that HMN-214 has a novel mechanism of action. Preclinical studies demonstrated HMN-214 possessed equal or more potent anti-tumor activity than that of other commercialized anti-cancer drugs, while adverse effects of HMN-214 is considered to be similar to those of typical anti-cancer drugs.
DWTI licensed-out the world-wide rights of HMN-214 to Nippon Shinyaku Co., Ltd. in March 2001. Nippon Shinyaku Co., Ltd. had completed Phase I trials in U.S.
(Clinical Indication: Glaucoma)
This drug is developed for the treatment of glaucoma through its intraocular pressure lowering action.
Since its strong intraocular pressure lowering action and nerve protecting action were confirmed in animal studies, etc., this drug is expected to serve as a glaucoma treatment drug with a novel action mechanism.
D. Western Therapeutics Institute, Inc. has licensed out the right to develop this product in Japan to Wakamoto Co., Ltd.. Preparation for non-clinical studies starts from year 2013.
|
|
|
| | | | |
| |
|
 |
